Yun-Sok Ha1, Jae-Wook Chung1, Seock Hwan Choi1, Jun Nyung Lee1, Hyun Tae Kim1, Tae-Hwan Kim1, Sung Kwang Chung1, Seok-Soo Byun2, Eu Chang Hwang3, Seok Ho Kang4, Sung-Hoo Hong5, Jinsoo Chung6, Cheol Kwak7, Yong-June Kim8, Tae Gyun Kwon9. 1. Department of Urology, Kyungpook National University Medical Center, Daegu, Korea. 2. Department of Urology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. 3. Department of Urology, Chonnam National University Hwasun Hospital, Jeonnam, Korea. 4. Department of Urology, Korea University School of Medicine, Seoul, Korea. 5. Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea. 6. Department of Urology, National Cancer Center, Goyang, Korea. 7. Department of Urology, Seoul National University College of Medicine, Seoul, Korea. 8. Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea. 9. Department of Urology, Kyungpook National University Medical Center, Daegu, Korea. Electronic address: tgkwon@knu.ac.kr.
Abstract
INTRODUCTION: The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS: The records of 274 patients with pRCC in the Korean renal cell carcinoma (KORCC) database were included for evaluation. Of the 274 patients, 118 had type 1 pRCC and 156 had type 2 pRCC. The patient characteristics, including clinicopathologic parameters, were investigated, and the oncologic outcomes were evaluated. RESULTS: The mean patient age was significantly older in the type 2 pRCC group. Compared with type 1 pRCC tumors, type 2 pRCC tumors were more often localized to the renal hilum (P = .030). Patients with type 2 pRCC had a greater incidence of Fuhrman grade 3 and 4 tumors than those with type 1 pRCC (78.8% vs. 22.8; P < .001). Tumor necrosis and capsular invasion were more frequently found in type 2 pRCC (P = .008 and P = .007, respectively). At a mean follow-up period of 38.0 months (interquartile range, 11.8-57.3 months), the subclassification of pRCC did not influence the prognosis of patients with pRCC. CONCLUSION: From the information available in the KORCC database, we identified significant differences in clinicopathologic variables, including age, Fuhrman grade, tumor location, tumor necrosis, and capsular invasion between type 1 and 2 pRCC. Although type 2 pRCC had more aggressive clinicopathologic characteristics, subclassification of pRCC did not affect the oncologic outcomes.
INTRODUCTION: The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS: The records of 274 patients with pRCC in the Korean renal cell carcinoma (KORCC) database were included for evaluation. Of the 274 patients, 118 had type 1 pRCC and 156 had type 2 pRCC. The patient characteristics, including clinicopathologic parameters, were investigated, and the oncologic outcomes were evaluated. RESULTS: The mean patient age was significantly older in the type 2 pRCC group. Compared with type 1 pRCCtumors, type 2 pRCCtumors were more often localized to the renal hilum (P = .030). Patients with type 2 pRCC had a greater incidence of Fuhrman grade 3 and 4 tumors than those with type 1 pRCC (78.8% vs. 22.8; P < .001). Tumor necrosis and capsular invasion were more frequently found in type 2 pRCC (P = .008 and P = .007, respectively). At a mean follow-up period of 38.0 months (interquartile range, 11.8-57.3 months), the subclassification of pRCC did not influence the prognosis of patients with pRCC. CONCLUSION: From the information available in the KORCC database, we identified significant differences in clinicopathologic variables, including age, Fuhrman grade, tumor location, tumor necrosis, and capsular invasion between type 1 and 2 pRCC. Although type 2 pRCC had more aggressive clinicopathologic characteristics, subclassification of pRCC did not affect the oncologic outcomes.
Authors: Sangjun Yoo; Dalsan You; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: J Cancer Res Clin Oncol Date: 2017-04-27 Impact factor: 4.553